As of the latest Form 4 filed Jul 6, 2026.
What Immunitybio Inc insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Buys plotted up, sells down; bar height is the disclosed dollar value (shares × reported price). Our Form 4 history is only complete from mid-2026, so early months are sparse — the series fills in as more filings land. Open-market purchases and sales only.
Newest filing first — the 14 most recent filings for IBRX.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-07-06 | 2026-07-02 | Cohen Cheryl Director | SSale | −131K | $9.50 | $1.25M | Yes (planned) | Form 4 ↗ |
| 2026-07-06 | 2026-07-02 | Cohen Cheryl, Director | MExercise | +56.0K | $2.98 | $167K | Yes (planned) | Form 4 ↗ |
| 2026-07-06 | 2026-07-01 | Selecky Christobel Director | SSale | −159K | $9.02 | $1.44M | Yes (planned) | Form 4 ↗ |
| 2026-07-06 | 2026-07-01 | Selecky Christobel, Director | MExercise | +124K | $2.99 | $372K | Yes (planned) | Form 4 ↗ |
| 2026-07-06 | 2026-07-01 | Selecky Christobel, Director | MExercise | +35.1K | $2.98 | $104K | Yes (planned) | Form 4 ↗ |
| 2026-07-01 | 2026-06-30 | Selecky Christobel Director | SSale | −1.00K | $9.00 | $9.00K | Yes (planned) | Form 4 ↗ |
| 2026-07-01 | 2026-06-30 | Selecky Christobel, Director | MExercise | +300.00 | $2.99 | $897.00 | Yes (planned) | Form 4 ↗ |
| 2026-07-01 | 2026-06-30 | Selecky Christobel, Director | MExercise | +700.00 | $2.98 | $2.09K | Yes (planned) | Form 4 ↗ |
| 2026-07-01 | 2026-06-29 | Selecky Christobel, Director | SSale | −95.7K | $9.01 | $862K | Yes (planned) | Form 4 ↗ |
| 2026-07-01 | 2026-06-29 | Selecky Christobel, Director | MExercise | +30.0K | $2.84 | $85.2K | Yes (planned) | Form 4 ↗ |
| 2026-07-01 | 2026-06-29 | Selecky Christobel, Director | MExercise | +33.5K | $2.99 | $100K | Yes (planned) | Form 4 ↗ |
| 2026-07-01 | 2026-06-29 | Selecky Christobel, Director | MExercise | +32.2K | $2.98 | $95.9K | Yes (planned) | Form 4 ↗ |
| 2026-06-26 | 2026-06-24 | Simon Barry J. Director | SSale | −25.0K | $7.88 | $197K | Yes (planned) | Form 4 ↗ |
| 2026-06-05 | 2026-06-04 | Simon Barry J. Director | SSale | −23.0K | $7.18 | $165K | Yes (planned) | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also IBRX’s full analysis or the market-wide insider trading feed. The tabs above jump to IBRX’s other SEC data.
Source: SEC Form 4 filings for IBRX, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.